VF
ABUS icon

Virtu Financial’s Arbutus Biopharma ABUS Stock Holding History

Virtu Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,923
Closed -$45K – 1349
2023
Q4 		$45K Buy
+17,923
New +$35.1K ﹤0.01% 1189
2023
Q2 		– Sell
-12,208
Closed -$37K – 1455
2023
Q1 		$37K Sell
12,208
-31,986
-72% -$90.2K ﹤0.01% 1148
2022
Q4 		$103K Buy
+44,194
New +$106K 0.01% 953
2022
Q3 		– Sell
-52,722
Closed -$143K – 1665
2022
Q2 		$143K Buy
+52,722
New +$135K 0.01% 856
2021
Q3 		– Sell
-93,196
Closed -$282K – 1439
2021
Q2 		$282K Buy
93,196
+29,255
+46% +$90.6K 0.03% 762
2021
Q1 		$213K Buy
63,941
+1,411
+2% +$5.45K 0.02% 1043
2020
Q4 		$222K Buy
+62,530
New +$219K 0.02% 791
2020
Q3 		– Sell
-17,147
Closed -$31K – 987
2020
Q2 		$31K Buy
+17,147
New +$28.1K ﹤0.01% 1075
2019
Q3 		– Sell
-24,548
Closed -$51K – 1387
2019
Q2 		$51K Buy
+24,548
New +$62.8K ﹤0.01% 1228
2018
Q1 		– Sell
-11,287
Closed -$57K – 1884
2017
Q4 		$57K Buy
+11,287
New +$66.2K ﹤0.01% 2054

Other funds holding ABUS

WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial's ABUS Position: Q1 2024 in Review

Virtu Financial sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 17,923 shares — an estimated $45K sold.

Virtu Financial first reported a position in ABUS in Q4 2017 and held it in 10 quarters. The position peaked at $282K in Q2 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

  • Virtu Financial reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 17,923 Arbutus Biopharma shares in Q1 2024, an estimated $45K.
  • Virtu Financial first reported a position in Arbutus Biopharma in Q4 2017 and held it in 10 quarters.
  • Virtu Financial's Arbutus Biopharma position peaked at $282K in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.